

Content of N2 Bulletin, 2014

REGULATORY NEWS

- FDA approves first drug for migraine prevention in adolescents. Susan Jeffrey
- FDA approves first sublingual allergen extract for the treatment of certain grass pollen allergies
- FDA approves Sovaldi for chronic hepatitis C
- FDA approves Otezla to treat psoriatic arthritis
- Novel stool DNA test may enhance colon cancer screening. Fran Lowry
- Laparoscopic power morcellation in hysterectomy and myomectomy: use discouraged due to increased risk in women with uterine fibroids

DRUGS SAFETY

- Ergot derivatives. New restrictions on use of medicines containing ergot derivatives
- Clopidogrel. Risk of acquired haemophilia
- Trimebutine: abuse, addiction and overdose
- Filgrastim and pegfilgrastim. Risk of potentially life-threatening capillary leak syndrome
- Calcitonin medicines. Important changes to availability and conditions of use
- Epidural corticosteroid injection: risk of rare but serious neurologic problems
- Bevacizumab. Necrotising fasciitis
- Rotavirus vaccination: risk of intussusception
- Ofatumumab and rituximab. New boxed warning, recommendations to decrease risk of hepatitis B reactivation
- Nitrofurantoin. Reminder on precautions for use, especially renal impairment in (elderly) patients

THE INTERESTING FACTS

- The ability of caffeine to fight against Alzheimer's disease was found
- The things surrounding the person every day are guilty in man's sterility
- Case of novel coronavirus in USA
- Biological model of lung will replace experimental animals

EVIDENCE BASED MEDICINES

- Vitamin D «insufficiency» in adults
- Old antibiotic for uncomplicated urinary tract infection. Pam Harrison
- Intra-articular hyaluronic acid: not for gonarthrosis

FOR GENERAL PHYSICIANS

- Osteoporosis management guidelines updated for women and men
- Type 1 diabetes: fewer complications with intensive insulin therapy